Quince Therapeutics Inc.
Organization details
- Legal name
- Quince Therapeutics Inc.
- Former names
- Cortexyme, Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- California
- Headquarters city
- South SAN Francisco
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- QNCX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001662774
- EIN
- 90-1024039
Board of directors
-
Brigette Roberts · Director · Chief Corp. Affairs OfficerSince 2026
-
Catherine M. Bonuccelli · DirectorSince 2026
-
Christopher J. Senner · DirectorSince 2023
-
David Lamond · DirectorSince 2023
-
Dirk Thye · Director · CEO and CMOSince 2023
-
James Elwood Valentine · DirectorSince 2026
-
John Drayton Wise · DirectorSince 2026
-
June Bray · DirectorSince 2023
-
Leone D. Patterson · DirectorSince 2026
-
Luca Benatti · DirectorSince 2023
-
Margaret McLoughlin · DirectorSince 2023
-
Rajiv Patni · DirectorSince 2024
-
Una S. Ryan · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 11, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
91.8%
Board connections
2 of this board's directors also sit on 3 other boards. 3 are in the same sector.
-
Kalaris Therapeutics Inc. Same sectorvia Leone D. Patterson
-
Nkarta Inc. Same sectorvia Leone D. Patterson
-
RenovoRx Inc. Same sectorvia Una S. Ryan
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $173,500
- 1 sale by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 9, 2026 | Militello John Officer (Chief Financial Officer) | Grant or award | +80,000 | — | — |
| Dec 26, 2025 | Luca Benatti Director | Open-market sale | −50,000 | $3.47 | $173,500 |
| Dec 10, 2025 | Dirk Thye Director, Officer (CEO and CMO) | Gift | −739,885 | — | — |
| Dec 10, 2025 | Dirk Thye Director, Officer (CEO and CMO) | Gift | +739,885 | — | — |
| Dec 5, 2025 | Hannah Brendan Officer (CBO, COO & CCO) | Option exercise | +2,271 | $0.55 | $1,249 |
| Dec 5, 2025 | Hannah Brendan Officer (CBO, COO & CCO) | Option exercise | +25,280 | $0.94 | $23,763 |
| Jun 18, 2025 | Hannah Brendan Officer (CBO, COO & CCO) | Grant or award | +37,736 | $1.20 | $45,283 |
| Jun 18, 2025 | Ryan Charles S. Officer (President) | Grant or award | +7,548 | $1.20 | $9,058 |
| Jun 18, 2025 | Dirk Thye Director, Officer (CEO and CMO) | Grant or award | +150,944 | $1.20 | $181,133 |
| Oct 23, 2024 | Luca Benatti Director | Other | +8,918 | — | — |
| Aug 30, 2024 | Dirk Thye Director, Officer (CEO AND CHIEF MEDICAL OFFICER) | Open-market purchase | +77,000 | $0.70 | $53,900 |
| Aug 29, 2024 | Dirk Thye Director, Officer (CEO AND CHIEF MEDICAL OFFICER) | Open-market purchase | +77,500 | $0.69 | $53,475 |
| Aug 21, 2024 | Hannah Brendan Officer (CHIEF BUSINESS OFFICER AND COO) | Open-market purchase | +2,280 | $0.61 | $1,391 |
| Aug 21, 2024 | Hannah Brendan Officer (CHIEF BUSINESS OFFICER AND COO) | Open-market purchase | +5,000 | $0.62 | $3,100 |
| Aug 21, 2024 | Hannah Brendan Officer (CHIEF BUSINESS OFFICER AND COO) | Open-market purchase | +23,565 | $0.63 | $14,846 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Quince Therapeutics Inc.
Who is the CEO of Quince Therapeutics Inc.?
Dirk Thye is Quince Therapeutics Inc.'s Chief Executive Officer.
How many directors are on Quince Therapeutics Inc.'s board?
Quince Therapeutics Inc.'s board has 13 directors: Brigette Roberts, Catherine M. Bonuccelli, Christopher J. Senner, David Lamond, Dirk Thye, James Elwood Valentine, John Drayton Wise, June Bray, Leone D. Patterson, Luca Benatti and 3 others.
Are Quince Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Quince Therapeutics Inc. insiders made no open-market purchases and sold $173,500 of shares in 1 sale on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="quince-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.